Multimeric il-15 soluble fusion molecules and methods of making and using same
AssigneeAltor BioScience Corporation
InventorsHing C. Wong, Peter Rhode, Bai Liu, Xiaoyun Zhu, Kai-Ping Han
Life of this patent
Estimating the term…
Abstract
The present invention features compositions and methods featuring ALT-803, a complex of an interleukin-15 (IL-15) superagonist mutant and a dimeric IL-15 receptor α/Fc fusion protein useful for enhancing an immune response against a neoplasia (e.g., multiple myeloma, melanoma, lymphoma) or a viral infection (e.g., human immunodeficiency virus).
Claims20
1-20. (canceled)
A fusion protein complex comprising 1) an IL-15 receptor alpha sushi-binding domain fused to an Fc domain (IL-15RαSu/Fc), and 2) a variant interleukin-15 polypeptide comprising an N72D mutation (IL-15N72D), wherein the complex comprises a dimeric IL-15RαSu/Fc and two IL-15N72D molecules, and wherein the IL-15RαSu domain is non-covalently bound to the IL-15N72D.
A nucleic acid sequence encoding a fusion protein complex comprising an IL-15RαSu/Fc and an IL-15N72D (IL-15N72D:IL-15RαSu/Fc;
- Alt-803), wherein the nucleic acid sequence encoding IL-15RαSu/Fc comprises SEQ ID NO:
- 57, and wherein the nucleic acid sequence encoding IL-15N72D comprises SEQ ID NO:
- 56.
A fusion protein complex comprising 1) an IL-15 receptor alpha sushi-binding domain fused to an Fc domain (IL-15RαSu/Fc), and 2) a wild type or variant interleukin-15 polypeptide comprising an N72D mutation (IL-15N72D), wherein a single-chain T-cell receptor (scTCR) is genetically fused to at least one of the IL-15RαSu/Fc and IL-15N72D, and wherein the complex comprises a dimeric IL-15RαSu/Fc and two non-covalently bound IL-15N72D molecules.
Dependencies are inferred from the claim text.